Literature DB >> 6127901

Pharmacokinetics of prenalterol in healthy subjects and patients with congestive heart failure.

O Rönn.   

Abstract

1. Prenalterol is rapidly and completely absorbed after oral administration with peak concentrations reached after 30 minutes. 2. Prenalterol is rapidly distributed to extravascular tissues after intravenous administration. 3. The extent of bioavailability after administration of prenalterol as a solution is about 25% of an intravenous dose. After administration of 20 mg prenalterol in a controlled release preparation the bioavailability is increased to about 45%. 4. The half-life of the elimination phase is close to 2 hours. 5. 60% of an intravenous dose and 15% of an oral dose is eliminated unchanged by renal excretion. The rest is mainly excreted as the sulphate ester of prenalterol.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6127901     DOI: 10.1111/j.0954-6820.1982.tb00838.x

Source DB:  PubMed          Journal:  Acta Med Scand Suppl        ISSN: 0365-463X


  5 in total

Review 1.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

2.  Pharmacokinetics of prenalterol after single and multiple administration of controlled release tablets to patients with congestive heart failure.

Authors:  U Dahlström; C Graffner; U Jonsson; K J Hoffmann; E Karlsson; P O Lagerström
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Pharmacokinetics and plasma-concentration-effect relationships of prenalterol in cardiac failure.

Authors:  E J Sainsbury; D Fitzpatrick; H Ikram; M G Nicholls; E A Espiner; J J Ashley
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of beta-agonists.

Authors:  D J Morgan
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

5.  Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum
Journal:  Crit Care       Date:  2021-06-10       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.